Kintor Pharmaceutical Ltd
HKEX:9939
Income Statement
Earnings Waterfall
Kintor Pharmaceutical Ltd
Revenue
|
0
CNY
|
Cost of Revenue
|
-42.2m
CNY
|
Gross Profit
|
-42.2m
CNY
|
Operating Expenses
|
-1B
CNY
|
Operating Income
|
-1.1B
CNY
|
Other Expenses
|
-1.1m
CNY
|
Net Income
|
-1.1B
CNY
|
Income Statement
Kintor Pharmaceutical Ltd
Dec-2020 | Jun-2021 | Dec-2021 | Jun-2022 | Dec-2022 | Jun-2023 | Dec-2023 | ||
---|---|---|---|---|---|---|---|---|
Revenue | ||||||||
Revenue |
0
N/A
|
0
N/A
|
34
N/A
|
34
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
|
Gross Profit | ||||||||
Cost of Revenue |
0
|
0
|
0
|
0
|
0
|
0
|
(42)
|
|
Gross Profit |
0
N/A
|
0
N/A
|
34
N/A
|
34
N/A
|
0
N/A
|
0
N/A
|
(42)
N/A
|
|
Operating Income | ||||||||
Operating Expenses |
(400)
|
(651)
|
(869)
|
(1 070)
|
(969)
|
(652)
|
(1 017)
|
|
Selling, General & Administrative |
(83)
|
(93)
|
(112)
|
(138)
|
(144)
|
(136)
|
(96)
|
|
Research & Development |
(325)
|
(463)
|
(763)
|
(947)
|
(819)
|
(532)
|
(939)
|
|
Depreciation & Amortization |
(6)
|
0
|
(10)
|
0
|
(18)
|
0
|
0
|
|
Other Operating Expenses |
15
|
(95)
|
17
|
15
|
11
|
16
|
17
|
|
Operating Income |
(400)
N/A
|
(651)
-63%
|
(835)
-28%
|
(1 036)
-24%
|
(969)
+6%
|
(652)
+33%
|
(1 060)
-63%
|
|
Pre-Tax Income | ||||||||
Interest Income Expense |
(109)
|
12
|
(7)
|
1
|
16
|
5
|
(9)
|
|
Non-Reccuring Items |
1
|
(0)
|
(0)
|
(0)
|
(1)
|
(1)
|
0
|
|
Pre-Tax Income |
(508)
N/A
|
(639)
-26%
|
(842)
-32%
|
(1 035)
-23%
|
(953)
+8%
|
(647)
+32%
|
(1 069)
-65%
|
|
Net Income | ||||||||
Tax Provision |
(0)
|
(0)
|
0
|
(0)
|
(1)
|
(1)
|
8
|
|
Income from Continuing Operations |
(508)
|
(639)
|
(842)
|
(1 035)
|
(954)
|
(648)
|
(1 061)
|
|
Net Income (Common) |
(508)
N/A
|
(639)
-26%
|
(842)
-32%
|
(1 035)
-23%
|
(954)
+8%
|
(648)
+32%
|
(1 061)
-64%
|
|
EPS (Diluted) |
-1.64
N/A
|
-1.84
-12%
|
-2.36
-28%
|
-2.84
-20%
|
-2.53
+11%
|
-1.51
+40%
|
-2.47
-64%
|